Sermorelin (5 mg) is a synthetic peptide composed of the first 29 amino acids of endogenous human growth hormone–releasing hormone (GHRH), representing the biologically active fragment responsible for stimulating growth hormone signaling in research models.

The peptide has a molecular formula of C₁₄₉H₂₄₆N₄₄O₄₂S and a molecular weight of approximately 3357.9 g/mol. It is supplied as a lyophilized powder in a 5 mg vial with high analytical purity, enabling precise dosing in controlled experimental settings.

Sermorelin is primarily used in research to examine the release of growth hormone (GH) and related signaling pathways.

Sermorelin (5mg) Key Features & Specs

• Subcategory: Muscle Growth & Performance Peptides
• Strength: 5 mg
• CAS: 86168-78-7
• Chemical Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
• Molecular Weight: 3357.9 g/mol
• Peptide Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
• Synonym: GHRH (1–29)

For laboratory research use only.

Sermorelin (5mg) Research Uses

Sermorelin is used to stimulate growth hormone release from the anterior pituitary, helping researchers study how GH secretion is regulated under physiological and experimental conditions.

The peptide is also used to examine:

• Hypothalamic-pituitary communication
• Pulsatile hormone release patterns
• Feedback mechanisms involving somatostatin and IGF-1
• Cellular signaling linked to endocrine adaptation

Sermorelin has expanded research applications in muscle and bone metabolism markers, sleep-related hormone rhythms, age-related changes in GH dynamics, and cardiometabolic signaling pathways.

It is used in research as a tool for observing transient signaling effects rather than as a therapeutic agent. Its short-acting nature and receptor-specific activity make it useful for dynamic testing in controlled environments.

Sermorelin (5mg) Insights & Observed Findings

Sermorelin is a short-acting growth hormone secretagogue with a rapid clearance profile.

• In clinical research, intravenous doses of approximately 1 µg/kg have been used to assess pituitary GH responsiveness and hormone reserve capacity under controlled experimental conditions.
• Subcutaneous administration, particularly in pediatric research cohorts, has been explored at doses around 30 µg/kg to assess changes in growth-related markers and hormone levels. Findings vary based on baseline endocrine function and should not be generalized.
• In preclinical research, Sermorelin is used in animal models to study the GH/IGF axis and its effects on protein metabolism, extracellular matrix activity, and tissue repair. It has also been explored in cardiac and vascular models to study the impact of hormone signaling on structural adaptation.
• Sermorelin is also used in laboratory method development, with techniques such as liquid chromatography–high-resolution mass spectrometry (LC-HRMS) employed to detect and quantify GHRH analogues. This reinforces its value as a research tool.

Sermorelin (5mg) Handling & Storage

• Store as a lyophilized powder at –20°C in a sealed container.
• Protect from light and moisture to maintain peptide stability.
• Allow the vial to reach room temperature before opening to reduce condensation.
• Reconstitute using a sterile aqueous solvent.
• After reconstitution, store the solution at 2–8°C for short-term use.
• Aliquot to minimize repeated freeze-thaw cycles and ensure consistency.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging. 2006;1(4):307-308. doi:10.2147/ciia.2006.1.4.307
2. Prakash A, Goa KL. Sermorelin. BioDrugs. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007
3. Pont L, Alechaga É, Terrero A, Monfort N, Ventura R. Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry. J Chromatogr A. 2020;1631:461548. doi:10.1016/j.chroma.2020.461548